508 related articles for article (PubMed ID: 31109041)
21. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
22. Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.
Quesada S; Fabbro M; Solassol J
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267439
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
Yang Y; Du N; Xie L; Jiang J; Mo J; Hong J; Mao D; Ng DM; Shi H
World J Surg Oncol; 2020 Jul; 18(1):151. PubMed ID: 32622363
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
26. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
Pacheco-Barcia V; Muñoz A; Castro E; Ballesteros AI; Marquina G; González-Díaz I; Colomer R; Romero-Laorden N
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740616
[No Abstract] [Full Text] [Related]
27. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches.
Dilmac S; Ozpolat B
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509303
[TBL] [Abstract][Full Text] [Related]
29. Niraparib in ovarian cancer: results to date and clinical potential.
Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F
Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841
[TBL] [Abstract][Full Text] [Related]
30. Niraparib for the treatment of ovarian cancer.
Kanjanapan Y; Lheureux S; Oza AM
Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
[TBL] [Abstract][Full Text] [Related]
31. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
[TBL] [Abstract][Full Text] [Related]
32. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency.
Yuan P; Ma N; Xu B
Med Res Rev; 2024 Jun; ():. PubMed ID: 38922930
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for Homologous Recombination Deficiency in Cancer.
Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
[TBL] [Abstract][Full Text] [Related]
34. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
Kaye SB
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i1-i3. PubMed ID: 27141062
[TBL] [Abstract][Full Text] [Related]
35. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
36. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Boussios S; Karihtala P; Moschetta M; Karathanasi A; Sadauskaite A; Rassy E; Pavlidis N
Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31374917
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
[TBL] [Abstract][Full Text] [Related]
38. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
39. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
40. RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis.
Tsantikidi A; Papazisis K; Floros T; Gazouli M; Papadopoulou E; Tsaousis G; Nasioulas G; Mester A; Milan KP; Gozman B; Afrasanie V; Stanculeanu DL; Trifanescu O; Pescaru F; Militaru C; Papadimitriou C
Oncol Lett; 2023 Nov; 26(5):480. PubMed ID: 37809048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
